Cargando…

The relationship of comorbidities to mortality and cause of death in patients with differentiated thyroid carcinoma

Understanding how comorbidities contribute to death in cancer patients is becoming an important topic. The present study assessed the role of comorbidities in overall mortality and causes of death in patients with differentiated thyroid carcinoma (DTC). This retrospective cohort study included 2070...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Young Ki, Hong, Namki, Park, Se Hee, Shin, Dong Yeob, Lee, Cho Rok, Kang, Sang-Wook, Lee, Jandee, Jeong, Jong Ju, Nam, Kee-Hyun, Chung, Woong Youn, Lee, Eun Jig
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6685995/
https://www.ncbi.nlm.nih.gov/pubmed/31391492
http://dx.doi.org/10.1038/s41598-019-47898-8
_version_ 1783442475820515328
author Lee, Young Ki
Hong, Namki
Park, Se Hee
Shin, Dong Yeob
Lee, Cho Rok
Kang, Sang-Wook
Lee, Jandee
Jeong, Jong Ju
Nam, Kee-Hyun
Chung, Woong Youn
Lee, Eun Jig
author_facet Lee, Young Ki
Hong, Namki
Park, Se Hee
Shin, Dong Yeob
Lee, Cho Rok
Kang, Sang-Wook
Lee, Jandee
Jeong, Jong Ju
Nam, Kee-Hyun
Chung, Woong Youn
Lee, Eun Jig
author_sort Lee, Young Ki
collection PubMed
description Understanding how comorbidities contribute to death in cancer patients is becoming an important topic. The present study assessed the role of comorbidities in overall mortality and causes of death in patients with differentiated thyroid carcinoma (DTC). This retrospective cohort study included 2070 patients who underwent thyroidectomy for DTC at a single institution between 2002 and 2005. Probabilities of overall, DTC-specific and other-cause death were examined according to the number of comorbidities, with consideration for competing events. The estimated 15-year cumulative incidences of overall, DTC-specific, and other-cause death were 7.3%, 1.6%, and 5.7%, respectively. Taking the group without comorbidities as a reference, we found that the group with 1–2 comorbidities and the group with ≥3 comorbidities had higher probabilities of other-cause death (subhazard ratios = 2.48 and 9.41, respectively; p < 0.01) and consequently shorter overall survival (hazard ratio = 1.95 and 5.33, respectively; p < 0.01), with adjustment for age, sex, and tumor-node-metastasis classification. In contrast, the probability of DTC-specific death was reduced in patients with ≥3 comorbidities (subhazard ratio = 6.81e-10, p < 0.01). For overall death, the relative proportion of death from DTC reduced when the number of comorbidities increased, and DTC-specific death was not observed in patients with ≥3 comorbidities. Our results show that death from DTC itself accounted for only a fraction of the overall deaths among patients who underwent surgery for DTC. Comorbidities increased overall mortality by increasing the probability of other-cause death. Patients with multiple comorbidities had a low probability of dying from DTC because they died earlier from comorbidities.
format Online
Article
Text
id pubmed-6685995
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-66859952019-08-12 The relationship of comorbidities to mortality and cause of death in patients with differentiated thyroid carcinoma Lee, Young Ki Hong, Namki Park, Se Hee Shin, Dong Yeob Lee, Cho Rok Kang, Sang-Wook Lee, Jandee Jeong, Jong Ju Nam, Kee-Hyun Chung, Woong Youn Lee, Eun Jig Sci Rep Article Understanding how comorbidities contribute to death in cancer patients is becoming an important topic. The present study assessed the role of comorbidities in overall mortality and causes of death in patients with differentiated thyroid carcinoma (DTC). This retrospective cohort study included 2070 patients who underwent thyroidectomy for DTC at a single institution between 2002 and 2005. Probabilities of overall, DTC-specific and other-cause death were examined according to the number of comorbidities, with consideration for competing events. The estimated 15-year cumulative incidences of overall, DTC-specific, and other-cause death were 7.3%, 1.6%, and 5.7%, respectively. Taking the group without comorbidities as a reference, we found that the group with 1–2 comorbidities and the group with ≥3 comorbidities had higher probabilities of other-cause death (subhazard ratios = 2.48 and 9.41, respectively; p < 0.01) and consequently shorter overall survival (hazard ratio = 1.95 and 5.33, respectively; p < 0.01), with adjustment for age, sex, and tumor-node-metastasis classification. In contrast, the probability of DTC-specific death was reduced in patients with ≥3 comorbidities (subhazard ratio = 6.81e-10, p < 0.01). For overall death, the relative proportion of death from DTC reduced when the number of comorbidities increased, and DTC-specific death was not observed in patients with ≥3 comorbidities. Our results show that death from DTC itself accounted for only a fraction of the overall deaths among patients who underwent surgery for DTC. Comorbidities increased overall mortality by increasing the probability of other-cause death. Patients with multiple comorbidities had a low probability of dying from DTC because they died earlier from comorbidities. Nature Publishing Group UK 2019-08-07 /pmc/articles/PMC6685995/ /pubmed/31391492 http://dx.doi.org/10.1038/s41598-019-47898-8 Text en © The Author(s) 2019 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Lee, Young Ki
Hong, Namki
Park, Se Hee
Shin, Dong Yeob
Lee, Cho Rok
Kang, Sang-Wook
Lee, Jandee
Jeong, Jong Ju
Nam, Kee-Hyun
Chung, Woong Youn
Lee, Eun Jig
The relationship of comorbidities to mortality and cause of death in patients with differentiated thyroid carcinoma
title The relationship of comorbidities to mortality and cause of death in patients with differentiated thyroid carcinoma
title_full The relationship of comorbidities to mortality and cause of death in patients with differentiated thyroid carcinoma
title_fullStr The relationship of comorbidities to mortality and cause of death in patients with differentiated thyroid carcinoma
title_full_unstemmed The relationship of comorbidities to mortality and cause of death in patients with differentiated thyroid carcinoma
title_short The relationship of comorbidities to mortality and cause of death in patients with differentiated thyroid carcinoma
title_sort relationship of comorbidities to mortality and cause of death in patients with differentiated thyroid carcinoma
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6685995/
https://www.ncbi.nlm.nih.gov/pubmed/31391492
http://dx.doi.org/10.1038/s41598-019-47898-8
work_keys_str_mv AT leeyoungki therelationshipofcomorbiditiestomortalityandcauseofdeathinpatientswithdifferentiatedthyroidcarcinoma
AT hongnamki therelationshipofcomorbiditiestomortalityandcauseofdeathinpatientswithdifferentiatedthyroidcarcinoma
AT parksehee therelationshipofcomorbiditiestomortalityandcauseofdeathinpatientswithdifferentiatedthyroidcarcinoma
AT shindongyeob therelationshipofcomorbiditiestomortalityandcauseofdeathinpatientswithdifferentiatedthyroidcarcinoma
AT leechorok therelationshipofcomorbiditiestomortalityandcauseofdeathinpatientswithdifferentiatedthyroidcarcinoma
AT kangsangwook therelationshipofcomorbiditiestomortalityandcauseofdeathinpatientswithdifferentiatedthyroidcarcinoma
AT leejandee therelationshipofcomorbiditiestomortalityandcauseofdeathinpatientswithdifferentiatedthyroidcarcinoma
AT jeongjongju therelationshipofcomorbiditiestomortalityandcauseofdeathinpatientswithdifferentiatedthyroidcarcinoma
AT namkeehyun therelationshipofcomorbiditiestomortalityandcauseofdeathinpatientswithdifferentiatedthyroidcarcinoma
AT chungwoongyoun therelationshipofcomorbiditiestomortalityandcauseofdeathinpatientswithdifferentiatedthyroidcarcinoma
AT leeeunjig therelationshipofcomorbiditiestomortalityandcauseofdeathinpatientswithdifferentiatedthyroidcarcinoma
AT leeyoungki relationshipofcomorbiditiestomortalityandcauseofdeathinpatientswithdifferentiatedthyroidcarcinoma
AT hongnamki relationshipofcomorbiditiestomortalityandcauseofdeathinpatientswithdifferentiatedthyroidcarcinoma
AT parksehee relationshipofcomorbiditiestomortalityandcauseofdeathinpatientswithdifferentiatedthyroidcarcinoma
AT shindongyeob relationshipofcomorbiditiestomortalityandcauseofdeathinpatientswithdifferentiatedthyroidcarcinoma
AT leechorok relationshipofcomorbiditiestomortalityandcauseofdeathinpatientswithdifferentiatedthyroidcarcinoma
AT kangsangwook relationshipofcomorbiditiestomortalityandcauseofdeathinpatientswithdifferentiatedthyroidcarcinoma
AT leejandee relationshipofcomorbiditiestomortalityandcauseofdeathinpatientswithdifferentiatedthyroidcarcinoma
AT jeongjongju relationshipofcomorbiditiestomortalityandcauseofdeathinpatientswithdifferentiatedthyroidcarcinoma
AT namkeehyun relationshipofcomorbiditiestomortalityandcauseofdeathinpatientswithdifferentiatedthyroidcarcinoma
AT chungwoongyoun relationshipofcomorbiditiestomortalityandcauseofdeathinpatientswithdifferentiatedthyroidcarcinoma
AT leeeunjig relationshipofcomorbiditiestomortalityandcauseofdeathinpatientswithdifferentiatedthyroidcarcinoma